Sai Parenteral's IPO
Sai Parenteral's IPO Timeline
About Sai Parenteral's IPO
Incorporated in 2001, Sai Parenterals Limited is a diversified pharmaceutical formulations company with capabilities in research, development, and manufacturing. The company operates through two primary verticals: branded generic formulations and contract development and manufacturing organisation (CDMO) services, catering to domestic and international markets. Its product portfolio spans multiple therapeutic areas such as, cardiovascular, neuropsychiatry, anti-diabetics, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology. The company offers a range of dosage forms such as tablets, capsules, liquid orals, ointments, and injectables. The company has capabilities in the injectables segment, including sterile manufacturing for critical care and penicillin-based therapies, with delivery formats such as dry powder injections, pre-filled syringes, ampoules, and vials.
Sai Parenteral's IPO Subscription Status
| Date | QIB | NII | Retail | Total |
|---|---|---|---|---|
| TBA | 0 | 0 | 0 | 0 |
| TBA | 0 | 0 | 0 | 0 |
Sai Parenteral's IPO Financial Status
| Particulars (in Rs. Crores) | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| Net Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
Sai Parenteral's IPO SWOT Analysis
Strengths
- Diversified Product Portfolio: The company has presence across multiple therapeutic segments and dosage forms.
- Manufacturing Infrastructure: The company has facilities for sterile and non-sterile formulations, including injectables.
- CDMO capabilities: It provides contract development and manufacturing services to customers.
- Domestic and International Presence: The company supplies products in India and overseas.
- Experienced Management: It is led by promoters with industry experience.
Weekness
- Regulatory Risk: The business is subject to approvals and compliance requirements.
- Raw Material Dependency: There is dependence on third-party suppliers for APIs and key inputs.
- Client Concentration: CDMO business may depend on key customers.
- Execution Risk: Growth depends on expansion and operational performance.
- Competition: The business operates in a competitive pharmaceutical market.
Frequently Asked Questions
What is the issue size of Sai Parenteral’s IPO?
The issue size for Sai Parenteral’s IPO is ₹409 Cr
What is 'pre-apply' for Sai Parenteral’s IPO?
You can apply for the Sai Parenteral’s IPO 2 days before the official subscription period begins using the pre-apply option.
How can I pre-apply for Sai Parenteral’s IPO?
Pre-applying for the Sai Parenteral’s IPO lets you apply before it officially opens. Click on the Apply Now link to apply for Sai Parenteral’s IPO on Religare Broking.
If I pre-apply for Sai Parenteral’s IPO, when will my order get placed?
Your order will be submitted to the exchange as soon as bidding for Sai Parenteral’s begins. You will receive a UPI request within 24 hours after the bidding starts.
When will I know if my Sai Parenteral’s IPO order is placed?
We will notify you when your Sai Parenteral’s order is placed with the exchange. |
What are the open and close dates of the Sai Parenteral’s IPO?
The open date is 24 Mar’2026 and the closing date is 27 Mar’2026 |
What is the lot size of the Sai Parenteral’s IPO?
The lot size of the IPO is 38 shares
What is the price band of the Sai Parenteral’s IPO?
The price band of the IPO is ₹372 to ₹392 per share |
Upcoming IPOs Announced & Expected
Rajputana Stainless IPO
Announced
Registrar information
Name
Bigshare Services Pvt.Ltd.
Phone number
+91-22-6263 8200
Email ID
ipo@bigshareonline.com
